Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,046 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study.
Qin S, Li J, Zhou A, Zhang Y, Yuan X, Zhu L, Qin B, Zeng S, Shen L, Yuan Y, Wang W, Liang J, Zhang X, Ye F, Chen P, Wang H, Yu Z, Yue L, Fang Y, Xiong J, Yang J, Wan Y, Yin X, Wang W, Xu N, Wang X, Xiao Z, Su H, Wang Y, Gu K, Tu S, Wang Z, Liu B, Hu X, Liu W, Li X. Qin S, et al. Among authors: wan y. Cancer Commun (Lond). 2024 Aug;44(8):910-914. doi: 10.1002/cac2.12586. Epub 2024 Jul 8. Cancer Commun (Lond). 2024. PMID: 38976318 Free PMC article. No abstract available.
Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study.
Qin S, Li J, Bai Y, Shu Y, Li W, Yin X, Cheng Y, Sun G, Deng Y, Zhong H, Li Y, Qian X, Zhang L, Zhang J, Chen K, Kang W; HLX04-mCRC03 Investigators. Qin S, et al. BioDrugs. 2021 Jul;35(4):445-458. doi: 10.1007/s40259-021-00484-9. Epub 2021 May 20. BioDrugs. 2021. PMID: 34014555 Free PMC article. Clinical Trial.
Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703).
Chi Y, Shu Y, Ba Y, Bai Y, Qin B, Wang X, Xiong J, Xu N, Zhang H, Zhou J, Xu J, Cheng Y, Feng J, Hu C, Chen Y, Chen Z, Wang J, Dang C, Wang J, Wan Y, Tang Y, Wang D, Liu J, Wu M, Deng Y, Li X, Li Y, Dong J, Jiang D, Li G, Wu Q, Li J, Qi Y, Sun Y, Cai J. Chi Y, et al. Among authors: wan y. Oncologist. 2021 Oct;26(10):e1693-e1703. doi: 10.1002/onco.13857. Epub 2021 Jun 25. Oncologist. 2021. PMID: 34105207 Free PMC article. Clinical Trial.
8,046 results